Navigation Links
Drug Firms Sue British Regulator Over Alzheimer's Drugs

Two drug firms and a charity for people with Alzheimer's disease began a legal challenge Monday against the downgrading of three anti-dementia drugs by British regulators.

In 2001 the National Institute for Health and Clinical Excellence (NICE), which issues guidance on how medicines should be used in Britain, recommended three drugs from US drugs giant Pfizer and Japan's Eisai.

But last year it changed its advice for patients with moderate Alzheimer's after consultation, saying instead that the drugs should only be considered as options.

The drugs -- Aricept, the brand name for donepezil; Exelon, also known as rivastigmine, and Reminyl, or galantamine -- had not proven especially effective for people with mild Alzheimer's, NICE said.

Pfizer and Eisai were due to argue in a four-day hearing at London's High Court that the effectiveness appraisal process for the drugs was unfair and that NICE's decision was both procedurally flawed and irrational.

Lawyer David Pannick, representing Eisai, told judge Linda Dobbs that the change in NICE's guidance meant that 96,600 people per year with mild Alzheimer's would not now receive the drugs.

The Alzheimer's Society, which represents people with dementia, claimed ahead of the hearing that NICE had acknowledged the drugs worked but, at a cost of 2.50 pounds per person per day (3.71 euros, 4.99 dollars), decided they were not cost effective.

"These treatments have benefitted so many families already -- where is the justice in NICE's decision to snatch them away?" Neil Hunt, chief executive of the charity, said.

Andrew Dillon, chief executive of NICE, countered that its recommendations were not unfair and were developed after three years of analysis and discussion with doctors, patients and drug makers.

"For Alzheimer's disease, drugs are only part of the care that needs to be offered," he said.

"Non-drug interventions have an important part to play and the evidence indicates that drugs are simply not effective for some patients."

Symptoms of Alzheimer's, the commonest form of dementia which affects about 450,000 people in Britain, include mood swings, confusion and withdrawal.


'"/>




Related medicine news :

1. Firms Told To Employ Those With Aspergers Syndrome
2. Drug Firms To Produce Single Pill AIDS Treatment
3. 12 Chinese Firms Appeal Against Court Ruling On Viagra
4. Drug Firms Meet Annan, Pledge on AIDS Medicines
5. Drug Firms Competing to Produce Cheap and Effective bird flu vaccine
6. US, India Firms Develop New Cure for Black Fever
7. Chemical Firms are Secretly Paying Scientists
8. Supreme Court Seeks Replies From Cola Firms
9. A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List
10. Nexus Between Psychiatrists and Drug Firms Dangerous, Say Critics
11. Milk Firms in Philippines Violate Breastfeeding Code: WHO
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für ... Apothekenbundes von Kenia eingeführt. Continue Reading ... ... Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic Implants ... Support) is Expected to Gain a Significant Market Share Owing ... Ailments  ... According to a new ... Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected to ...
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... in red, while the Dow Jones Industrial Average managed to ... of US markets, which prompted Stock-callers this morning to look ... (NASDAQ: NUVA ), Smith & Nephew PLC (NYSE: ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ...
Breaking Medicine Technology: